Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure
- 1Department of Cardiology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan
- 2Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, Yufu, Oita, Japan
- 3Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.
Related
- Reduction in Rheumatoid Factor and Matrix Metalloproteinase-3 With Successful Glucocorticoid Withdrawal After Initiation of Pemafibrate in a Patient With Rheumatoid Arthritis and Hypertriglyceridemia: A Case Report.
- Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan: An Interrupted Time Series Analysis.
- Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis
- Marked reduction of homogentisic acid with nitisinone in a child with alkaptonuria: a case report
- Marked Monocytic Erythrophagocytosis in a Patient With Cold Agglutinin Disease.
BibTeX
@article{otani2026marked,
title = {{Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure}},
author = {Naoyuki Otani and Takushi Sugiyama and Yasuhiro Maejima},
journal = {BMJ Case Reports},
year = {2026},
month = nov,
doi = {10.1136/bcr-2026-275554},
url = {https://doi.org/10.1136/bcr-2026-275554},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure
AU - Naoyuki Otani
AU - Takushi Sugiyama
AU - Yasuhiro Maejima
PY - 2026
DA - 2026/11/05
JO - BMJ Case Reports
DO - 10.1136/bcr-2026-275554
UR - https://doi.org/10.1136/bcr-2026-275554
AB - Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.
SN - 1757-790X
ER -